overtreatment Archives - Well Referenced

Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis

This 2018 systematic review and meta-analysis evaluated the efficacy and risks of PSA-based prostate cancer screening across five randomized controlled trials involving over 721,000 men. The findings indicate that PSA screening may lead to a small reduction in prostate cancer-specific mortality over 10 years (incidence rate ratio [IRR] 0.96; 95%

June 26, 2025 No Comments

Long-term active surveillance for prostate cancer: answers and questions

This 2014 editorial by Dr. Matthew R. Cooperberg discusses the evolving role of active surveillance (AS) in managing low-risk prostate cancer. It emphasizes that AS is a viable strategy to avoid overtreatment and associated morbidities in men with indolent disease. The article highlights the need for standardized AS protocols, including

June 26, 2025 No Comments

Gleason score 3+3=6 prostatic adenocarcinoma is not benign and the current debate is unhelpful to clinicians and patients

This article critically examines the persistent debate over the classification of Gleason score (GS) 3+3=6 prostate adenocarcinoma. Despite its typically indolent clinical course and low likelihood of metastasis, the tumor meets histopathologic criteria for malignancy and shares molecular features with more aggressive forms. The authors argue that labeling GS 3+3=6

June 26, 2025 No Comments

A 16-yr Follow-Up of the European Randomized Study of Screening for Prostate Cancer

This article presents a 16-year follow-up of the European Randomized Study of Screening for Prostate Cancer, which evaluates the long-term outcomes of prostate cancer screening using PSA testing. The study found that screening led to a modest reduction in prostate cancer mortality, but with a higher risk of overdiagnosis and

June 26, 2025 No Comments

Active Surveillance for Intermediate Risk Prostate Cancer

This article reviews the role of active surveillance in managing intermediate-risk prostate cancer. It examines current evidence supporting the use of active surveillance for this patient group, considering factors like tumor characteristics, patient age, and life expectancy. The study suggests that active surveillance can be a reasonable alternative to aggressive

June 26, 2025 No Comments

Active Surveillance for Low-Risk Cancers – A Viable Solution to Overtreatment?

This article discusses the use of active surveillance as a strategy to manage low-risk cancers and avoid overtreatment. It explores the benefits of closely monitoring patients with low-risk cancer types, such as prostate and thyroid cancers, rather than pursuing immediate aggressive treatments. The study suggests that active surveillance can reduce

June 26, 2025 No Comments

Active Surveillance for Low-Risk Prostate Cancer-An Evolving International Standard of Care

This article explores the evolving role of active surveillance in the management of low-risk prostate cancer. The study reviews international guidelines and clinical outcomes, highlighting the benefits of active surveillance in avoiding overtreatment and preserving quality of life. It emphasizes that with proper patient selection and monitoring, active surveillance is

June 26, 2025 No Comments

Prostate cancer–uncertainty and a way forward

This editorial discusses the findings of a study comparing radical prostatectomy to observation in men with localized prostate cancer, emphasizing the uncertainty in determining the optimal management strategy. The study found no significant difference in all-cause mortality between men undergoing surgery and those under observation, though surgery reduced disease-specific mortality

June 26, 2025 No Comments

Tag: overtreatment